Form 4 for IONS IONIS PHARMACEUTICALS INC
Accepted 2024-10-17 00:00:00 ET · period of report 2024-10-15 · accession 0000874015-24-000229 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-10-17 | 2024-10-15 | IONS | Swayze Eric | EVP Research | M - OptEx | $0.00 | +125 | 210 | +147% | $0 |
| DI | 2024-10-17 | 2024-10-16 | IONS | Swayze Eric | EVP Research | S - Sale+OE | $38.31 | -53 | 157 | -25% | -$2,030 |
| DI | 2024-10-17 | 2024-10-15 | IONS | Swayze Eric | EVP Research | M - OptEx | $0.00 | -125 | 426 | -23% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-15 | M | A | 125 | $0.00 | 210 | I by Son | — | — | (F1) Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. |
| 2 | Common | Common Stock | 2024-10-16 | S | D | 53 | $38.31 | 157 | I by Son | — | — | (F2) The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. |
| 3 | Derivative | Restricted Stock Unit | 2024-10-15 | M | D | 125 | $0.00 | 426 | I by Son | $0.00 · — to — | 125 Common Stock | (F3) Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. (F4) Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. |